A DOSE-FINDING, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH EFIMOSFERMIN ALFA IN ADULT PARTICIPANTS WITH ALCOHOL-RELATED LIVER DISEASE (ALD) (ALLSTAR)

Registry ID

306837

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Last update

2026-07-14

Conditions

• LIVER DISEASE

Related clinical trials

• A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK4532990 FOR STEATOHEPATITIS IN ADULTS WITH ALCOHOL RELATED LIVER DISEASE (ALD)
• EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER DISEASE
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FAZIRSIRAN IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE WITH METAVIR STAGE F1 FIBROSIS

View on source registry